Voloridge Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-86,599
Closed -$2.77M 1374
2024
Q3
$2.77M Buy
86,599
+8,876
+11% +$332K 0.01% 890
2024
Q2
$2.93M Buy
77,723
+63,395
+442% +$2.67M 0.01% 876
2024
Q1
$705K Sell
14,328
-486,421
-97% -$22.5M ﹤0.01% 1013
2023
Q4
$18.3M Buy
500,749
+426,246
+572% +$11.1M 0.07% 342
2023
Q3
$1.72M Sell
74,503
-117,747
-61% -$3.22M 0.01% 963
2023
Q2
$5.04M Sell
192,250
-158,544
-45% -$4.17M 0.02% 670
2023
Q1
$9.03M Buy
350,794
+23,524
+7% +$688K 0.04% 475
2022
Q4
$8.51M Sell
327,270
-123,724
-27% -$3.05M 0.05% 477
2022
Q3
$12.9M Buy
450,994
+8,662
+2% +$248K 0.07% 374
2022
Q2
$10.9M Buy
442,332
+422,918
+2,178% +$15.5M 0.06% 412
2022
Q1
$1.1M Buy
19,414
+11,262
+138% +$644K 0.01% 1111
2021
Q4
$505K Sell
8,152
-4,826
-37% -$319K ﹤0.01% 1407
2021
Q3
$823K Sell
12,978
-40,538
-76% -$3.12M 0.01% 1336
2021
Q2
$4.41M Buy
53,516
+1,759
+3% +$134K 0.03% 690
2021
Q1
$3.81M Buy
51,757
+39,800
+333% +$3.12M 0.03% 612
2020
Q4
$867K Buy
+11,957
New +$770K 0.01% 1009

Other funds holding SWTX

Voloridge Investment Management's SWTX Position: Q4 2024 in Review

Voloridge Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 86,599 shares — an estimated $2.77M sold.

Voloridge Investment Management first reported a position in SWTX in Q4 2020 and held it in 16 quarters. The position peaked at $18.3M in Q4 2023. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Voloridge Investment Management reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 86,599 SpringWorks Therapeutics shares in Q4 2024, an estimated $2.77M.
  • Voloridge Investment Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 16 quarters.
  • Voloridge Investment Management's SpringWorks Therapeutics position peaked at $18.3M in Q4 2023.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Voloridge Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.